<DOC>
	<DOCNO>NCT03003195</DOCNO>
	<brief_summary>The purpose research compare effect use new experimental vaccine standard treatment treat metastatic cancer .</brief_summary>
	<brief_title>Vaccination Patients With Metastatic Cancer</brief_title>
	<detailed_description>After sign Institutional Review Board ( IRB ) approve consent , subject metastatic cancer enrol . The vaccine dose prepared dispensed University Arkansas Medical Sciences ( UAMS ) Pharmacy follow manufacturer 's instruction . Subjects receive 1.0 mL subcutaneous injection vaccine 4 separate occasion . The vaccine administer rotate site limbs abdomen . The study last approximately 12 month .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Neoplasms Site</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>Subjects race clinical Stage IV cancer type , stag accord American Joint Commission Cancer ( AJCC ) , sixth edition , receive line standard treatment specific cancer stable disease well least two month invite participate . Subjects race clinical Stage IV cancer type , stag accord American Joint Commission Cancer ( AJCC ) , sixth edition , standard treatment option specific cancer ( Patients whose standard care consist watchful wait ) fulfill eligibility criterion invite participate . Measurable evaluable disease . Patients boneonly disease allow participate . Ages 18 year old . ECOG Performance status 0 , 1 2 . White blood cell ( WBC ) count ≥ 3,000/mm3 within 3 week prior registration Platelet count ≥ 100,000/mm3 prior registration Serum glutamicoxaloacetic transaminase ( SGOT ) ≤ 2 x institutional upper limit ( IUL ) normal obtain within 3 week prior registration Aspartate aminotransferase test ( AST ) ≤ 2 x institutional upper limit ( IUL ) normal obtain within 3 week prior registration Bilirubin ≤ 2 x institutional upper limit ( IUL ) normal obtain within 3 week prior registration . Serum creatinine ≤ 1.8 mg/dl obtain within 3 week prior registration . Must sign inform consent document approve UAMS Institutional Review Board ( IRB ) . Active infection require treatment antibiotic . Existing diagnosis history organic brain syndrome precludes participation full protocol . Existing diagnosis history significant impairment basal cognitive function might preclude participation full protocol . Other current malignancy . Subjects prior history time situ cancer , include lobular carcinoma situ breast , cervical cancer situ , atypical melanocytic hyperplasia Clark I melanoma situ , basal squamous skin cancer eligible , provide diseasefree malignancy time registration . Subjects malignancies one treat eligible continuously disease free ( old cancer ) ≥ 5 year prior time registration . Existing diagnosis history autoimmune disorder condition immunosuppression . This include , limited , treated corticosteroid , include oral steroid ( i.e . prednisone , dexamethasone [ except use antiemetic standard therapy ] ) , continuous use topical steroid cream ointment steroidcontaining inhaler . Subjects systemic steroid require 6week washout period . Subjects discontinue use class medication least 6 week prior registration eligible , judgment treat physician , subject likely require class drug treatment period . Replacement dose steroid subject adrenal insufficiency allow . Pregnancy breast feeding , due unknown effect peptide/mimotope vaccine fetus infant . Women childbearing potential must negative urine pregnancy test within 72 hour prior receive first dose study drug , must counsel use accept effective method contraception treatment period 18 month complete discontinue treatment . Accepted method include oral contraceptive , barrier method , IUDs , abstinence . Any significant medical psychiatric condition , opinion enrol investigator , may interfere consent compliance treatment . Patients receive checkpoint inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>